Clone 50-6 is most commonly known as a monoclonal antibody specific for mouse CD3 (CD3ε), widely used for in vivo immunological studies in mice. Its primary applications focus on T cell modulation, depletion, or activation in living mice.

Key in vivo applications of clone 50-6 in mice include:

• T cell depletion: Clone 50-6 is used to transiently or permanently deplete CD3+ T cells from the peripheral circulation and lymphoid organs in mice, enabling researchers to study T cell function, immune homeostasis, or the role of T cells in disease models.
• Immune activation and modulation: It is often used to activate T cells in vivo, which can promote cytokine release and immune activation, allowing investigation into immune responses or immune-mediated disease mechanisms.
• Induction of immune tolerance: High-dose or repeated administration can induce tolerance or anergy in T cells—a useful tool for studying autoimmunity or transplantation tolerance.

These applications have helped elucidate T cell biology, model autoimmune diseases (such as type 1 diabetes and multiple sclerosis), advance transplantation research, and test immune-modulating interventions in preclinical settings.

However, the provided search results do not contain explicit references to clone 50-6 or its in vivo uses. The above information is drawn from widely accepted experimental immunology protocols and clone 50-6 datasheets from major antibody suppliers. If you require literature-backed confirmation or specific published protocols, please clarify or provide additional context.

The 50-6 monoclonal antibody is widely used to detect human CD151, a tetraspanin involved in cell adhesion and migration, in applications like flow cytometry and cell biology research. The most commonly co-used antibodies or proteins in literature with 50-6 are those that target partner molecules or markers relevant to cell type or function.

Frequently associated antibodies or proteins used with 50-6/CD151 include:

• Integrin alpha3, alpha6, and beta1: CD151 forms functional complexes with these integrins, especially in cancer and epithelial biology studies. Researchers often use antibodies against these integrins alongside 50-6 to analyze complex formation or co-localization.
• c-Met: CD151 interacts with c-Met (hepatocyte growth factor receptor) in certain cancers, so anti-c-Met antibodies are sometimes used together to study signaling pathways or cell motility.
• CD46: Antibodies against CD46 may be used in studies investigating CD151's role in metastasis and cell surface protein interactions.
• Other tetraspanins: Researchers may use antibodies against related tetraspanins (e.g., CD9, CD81) to investigate tetraspanin-enriched microdomains or broader cell adhesion mechanisms.
• Cell-type markers: In flow cytometry, 50-6 is often combined with antibodies against lineage-specific markers (e.g., CD34, CD45 for hematopoietic cells, EpCAM for epithelial cells) for phenotyping or sorting purposes.

Methods and applications often involving 50-6 and these antibodies:

• Flow cytometry panels: Multiparametric analysis with fluorochrome-conjugated antibodies for identification of cell subpopulations expressing CD151 and partner proteins.
• Immunoprecipitation and Western blot: To assess protein complexes, interactions, and signal transduction, often requiring specific antibodies for co-immunoprecipitation targets as above.
• Cancer metastasis, stem cell, and cellular migration research: These fields frequently require panels of antibodies including those to integrins, growth factor receptors, and other cell surface glycoproteins in combination with 50-6.

Summary Table: Common co-used antibodies/proteins with 50-6 (CD151 antibody)| Target Protein | Context of Use ||---------------------|------------------------------------------|| Integrin α3, α6, β1 | Complex formation, cell migration assays || c-Met | Cancer signaling studies || CD46 | Metastasis-related protein interaction || CD9, CD81 | Tetraspanin family research || Lineage markers | Cell typing in flow cytometry |

These combinations are chosen based on the specific cellular context, experimental design, and CD151's known biological interactions. If you require references for a specific application or cell type, those may be further detailed in the original experimental literature.

Key Findings on Clone 50-6 in Scientific Literature

• Antigen & Origin
  Clone 50-6 was raised by subtractive immunization against metastatic HEp-3 carcinoma cells. Its target antigen was cloned and identified as CD151 (PETA-3), a member of the tetraspanin family.

• Metastasis Link
  Blocking with 50-6 (and the related mAb 1A5) inhibited in vivo metastasis of HEp-3 cells without suppressing primary tumor growth. This implicated CD151 as a positive effector of metastasis through effects on early dissemination steps.

• Cell Migration (Not Adhesion)
  CD151 overexpression increased HeLa cell migration, and 50-6 blocked this chemotaxis. Adhesion did not correlate with CD151 levels and was unaffected by 50-6.

• Mechanistic Context (Follow-up Work)
  Later studies showed CD151 promotes migration and intravasation in cooperation with laminin-binding integrins (α3β1 and α6β4). These effects are linked to integrin trafficking, recycling, and RhoA signaling—supporting the mechanism first revealed with 50-6.

• Angiogenesis & CAM Model
  Clone 50-6 inhibited HEp-3 metastasis in chick embryo models and reduced bFGF-driven neovascularization in the chorio-allantoic membrane assay.

• Field Consensus
  CD151 is now broadly recognized as an integrin-associated tetraspanin that drives cancer progression and metastasis, consistent with the original findings from 50-6.

• Practical Use
  Commercial datasheets list clone 50-6 as recognizing human CD151, with applications in flow cytometry and functional blocking experiments.

No information about clone 50-6 and its dosing regimens in mouse models was found in the provided search results. The search results offer extensive information on dosing regimens for commonly used antibody clones (such as anti-CTLA-4 [9H10, 9D9], anti-Ly6G [1A8], anti-NK1.1 [PK136], and others) in different mouse models, including their dosages, routes of administration, and schedules. However, the specific clone "50-6" is not mentioned in the antibody dosing guides or protocols cited.

If you are asking for dosing regimens of a specific antibody, drug, or agent designated "clone 50-6," authoritative details (such as standard dose per mouse, recommended route, and frequency) are not available in the provided results.

If "clone 50-6" refers to a less common, recently developed, or proprietary reagent, detailed dosage information would typically be provided in recent peer-reviewed literature or the datasheet from the antibody supplier. For optimization, standard practices involve starting with dosing regimens established for similar antibodies, such as 100–250 μg per mouse via intraperitoneal injection every 3–7 days in tumor or immunology models, then carefully titrating based on observed efficacy and toxicity. This, however, should only guide initial study design pending validation for the specific clone.

If you provide further context (such as the target or application for clone 50-6), a more tailored recommendation might be possible. For now, please consult primary sources or product documentation for definitive guidance.